Home
/
Fortress Biotech, Inc.
/
Financials
/
Quarterly
Fortress Biotech, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Fortress Biotech, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$17.63M
Nov 14, 2025
Q2
2025
Jun 30, 2025
$16.41M
Aug 14, 2025
Q3
2025
Sep 30, 2024
$14.63M
Nov 14, 2025
Q2
2025
Jun 30, 2024
$14.90M
Aug 14, 2025
Q1
2024
Mar 31, 2024
$13.03M
May 15, 2024
Q3
2024
Sep 30, 2023
$34.75M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$17.39M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$12.43M
May 15, 2024
Q3
2023
Sep 30, 2022
$16.53M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$18.89M
Aug 14, 2023
Q1
2023
Mar 31, 2022
$23.93M
May 15, 2023
Q3
2022
Sep 30, 2021
$21.09M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$17.84M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$11.59M
May 12, 2022
Q3
2021
Sep 30, 2020
$9.48M
Nov 15, 2021
Q2
2021
Jun 30, 2020
$9.46M
Aug 16, 2021
Q1
2021
Mar 31, 2020
$12.92M
May 17, 2021
Q3
2020
Sep 30, 2019
$9.77M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$9.25M
Aug 10, 2020
Q1
2020
Mar 31, 2019
$6.48M
May 11, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2017
Mar 31, 2017
$44.68M
May 10, 2017
Q3
2016
Sep 30, 2016
$975.0K
Nov 9, 2016
Q2
2016
Jun 30, 2016
$2.23M
Aug 9, 2016
Q1
2017
Mar 31, 2016
$660.0K
May 10, 2017
Q3
2016
Sep 30, 2015
$25.0K
Nov 9, 2016
Q2
2016
Jun 30, 2015
$0
Aug 9, 2016
Q1
2016
Mar 31, 2015
$500.0K
May 10, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.85M
Nov 14, 2025
Q2
2025
Jun 30, 2025
$15.49M
Aug 14, 2025
Q1
2025
Mar 31, 2025
($10.58M)
May 15, 2025
Q3
2025
Sep 30, 2024
($12.87M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($10.95M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($15.42M)
May 15, 2025
Q3
2024
Sep 30, 2023
($5.05M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($24.78M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($21.54M)
May 15, 2024
Q3
2023
Sep 30, 2022
($22.51M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($21.36M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($15.76M)
May 15, 2023
Q3
2022
Sep 30, 2021
($20.78M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($3.54M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($8.82M)
May 12, 2022
Q3
2021
Sep 30, 2020
($15.55M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($13.31M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($12.37M)
May 17, 2021
Q3
2020
Sep 30, 2019
($12.76M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($13.10M)
Aug 10, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($6.81M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($36.47M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($22.32M)
May 15, 2025
Q3
2025
Sep 30, 2024
($22.10M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($27.79M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($36.57M)
May 15, 2025
Q3
2024
Sep 30, 2023
($13.76M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($50.11M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($58.87M)
May 15, 2024
Q3
2023
Sep 30, 2022
($50.73M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($50.93M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($47.27M)
May 15, 2023
Q3
2022
Sep 30, 2021
($49.92M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($42.86M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($30.02M)
May 12, 2022
Q3
2021
Sep 30, 2020
($23.04M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($25.40M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($21.53M)
May 17, 2021
Q3
2020
Sep 30, 2019
($22.54M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($25.29M)
Aug 10, 2020